[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539253":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":28,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"dalpiciclib",null,"dalpiciclib oral day 1-21, every 28 days",[13],"Drug: dalpiciclib",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":10},"DRUG",[9],[19],{"name":20,"affiliation":21,"role":22},"Wenjin Yin","Renji Hospital, School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","86(21)68385569","yinwenjin@renji.com",[29],{"facility":21,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Shanghai","200127","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":22,"investigatorFullName":20,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Deputy Chief of Breast Surgery Department","100539253","dalpiciclib-in-hrher2--abc-100539253",false,"NCT06301438","Dalpiciclib in HR+\u002FHER2- ABC","Efficacy and Safety of Dalpiciclib in HR+\u002FHER2- Advanced Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Histologically confirmed advanced breast cancer\n* Hormone receptor-positive and human epidermal growth factor receptor 2-negative\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* History of immunodeficiency","ALL","18 Years",{"count":55,"type":56},103,"ESTIMATED","OBSERVATIONAL","To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive\u002FHER2-positive advanced breast cancer.",[60],"Advanced Breast Cancer","2026-02-01",{"date":63,"type":64},"2026-02-03","ACTUAL",{"date":66,"type":64},"2024-05-03",{"date":68,"type":56},"2028-12",{"name":5,"class":6},1]